RECURRENT GLIOBLASTOMA

Glioblastoma multiforme belongs to the most aggressive tumors with very short-time survival. Treatment of this disease is very limited and only temozolomide and radiation is widely used in clinical practice. New biomarkers could allow deeper insight in gliomagenesis and also can help to facilitate possible targets in prognosis and prediction which may lead to development of new therapy regimes. In our study, status of genes and chromosomes (MDM2/ chr.12, EGFR1/ chr.7, BCR/ chr.22, P53/ chr.17, RB1/ chr.13, C-MET/ chr.7, PTEN/ 10p, 19q/ 19p, 1p/ 1q, 9p/ chr.9) was investigated, using FISH probes. We examined 25 patients with recurrent glioblastoma and we established cooperation with other oncology groups for obtaining other samples. Control group comprising of 111 patients with glioblastoma was used for comparison (both groups with treatment regime 54 Gy and 40 days of temozolomide). Statistical analysis revealed significant difference in age (p = 0.0002) and loss of p53 (p = 0.093) between control group and recurrent glioblastoma group. Other significant relevances of this study are summarized and clinical relevance of our findings will be associated with intended additional study.

Supported by NT 13581; TE02000058; LF_2014_019; CZ.1.05/ 2.1.00/ 01.0030.